How A Wall Street Analyst Started A $4 Billion Obesity Drug Company
The story behind how a Wall Street analyst built a $4 billion obesity-drug company centers on Brian Lian, the founder and CEO of Viking Therapeutics. His journey shows how financial expertise, scientific knowledge, and timing in a fast-growing healthcare market can create a billion-dollar biotech startup.
From Wall Street Analyst to Biotech Founder
Before launching his company, Brian Lian spent nearly a decade as a Wall Street equity analyst studying small and mid-size biotechnology firms. His job was to analyze pharmaceutical companies developing treatments for diseases such as diabetes and metabolic disorders.
In 2012, a meeting with pharmaceutical executives changed his career path. During that conversation, he learned that a company had recently acquired several diabetes drug candidates and was willing to license them out. Instead of just analyzing the opportunity for investors, Lian decided to leave Wall Street and build his own biotech company to develop those drugs.
Launching Viking Therapeutics
- Lian founded Viking Therapeutics with a bold strategy:
- License promising early-stage drug candidates.
- Develop treatments focused on metabolic diseases, including obesity and fatty-liver disease.
- Raise funding through investors and eventually public markets.
He successfully convinced Ligand Pharmaceuticals to
License five drug programs to his startup.
Invest $2.5 million to help launch the company
For someone who had never started a company before, this early partnership was critical.
Taking the Company Public
Starting a biotech firm is extremely risky because:
- Drug development can take 10–15 years.
- Clinical trials are expensive.
- Many drug candidates fail before approval.
Despite these challenges, Viking eventually went public through an IPO in 2015, giving the company the capital needed to continue drug development.
The IPO transformed Viking from a small startup into a publicly traded biotech company and allowed it to expand research programs.
Entering the Obesity Drug Race
Initially, Viking focused on fatty liver disease treatments, but Lian later recognized a massive opportunity in the obesity drug market.
The sector exploded after the success of drugs such as:
- Ozempic
- Wegovy
- Zepbound
These medications belong to a class called GLP-1 drugs, which help people lose weight by regulating appetite and blood sugar.
With obesity affecting around 40% of adults in the U.S., analysts believe the global market for weight-loss drugs could reach $100 billion annually by 2030.
Recognizing this opportunity, Viking began developing its own next-generation obesity drug.
Viking’s Obesity Drug Development
Viking’s lead obesity therapy is designed to work as both:
- An injectable treatment (in Phase 3 clinical trials)
- A pill version (in Phase 2 trials)
Why the Company Is Worth $4 Billion
Even though Viking does not yet have a drug on the market, investors value the company at about $4 billion because of its promising pipeline and the huge obesity-drug market opportunity.
Several factors drive this valuation:
- Huge demand for weight-loss drugs worldwide.
- Strong clinical trial results so far.
- Interest from major pharmaceutical companies looking to acquire promising biotech startups.
- Hedge funds and institutional investors backing the company.
Because of this potential, Viking is often seen as a possible acquisition target for large pharma companies.
Early trial results have shown promising outcomes:
- Up to 14.7% body-weight loss with the injectable version
- Around 8.3% weight loss with the pill version
If clinical trials continue to succeed, the company could apply for regulatory approval in the late 2020s.
Competition in the Obesity Drug Market
The obesity drug industry is currently dominated by major pharmaceutical companies such as:
- Novo Nordisk
- Eli Lilly
However, dozens of startups are trying to challenge them. Analysts estimate that more than 60 companies are developing over 120 obesity drugs worldwide.
This intense competition means that the next breakthrough treatment could be worth tens of billions of dollars.
Also Read:-
10 Effective Steps to Win Clients on LinkedIn Without Spam or Scripts
Top 20 Must-Visit Cities Around the World in 2026 – Time Out Picks
BTS Comeback Show and Documentary to Be Streamed on Netflix
